Investigating kidney injury in cancer patients using immune checkpoint inhibitors and antibiotics
Acute Kidney Injury with Immune Checkpoint Inhibitors and Beta-Lactam Antibiotics
This study is looking at how certain cancer treatments can sometimes harm the kidneys, especially when used with common antibiotics, to help doctors find ways to spot and prevent kidney problems early, making treatment safer for patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10998392 on NIH RePORTER |
What this research studies
This research focuses on understanding acute kidney injury (AKI) as a serious side effect of immune checkpoint inhibitors (ICIs), a new class of cancer treatments. It aims to identify risk factors and monitoring parameters for AKI, particularly in patients receiving ICIs alongside beta-lactam antibiotics, which are commonly used in cancer care. By studying the mechanisms behind this kidney injury, the research seeks to improve early detection and prevention strategies, ultimately enhancing patient safety and treatment outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients aged 65 and older who are receiving immune checkpoint inhibitors and beta-lactam antibiotics.
Not a fit: Patients who are not receiving immune checkpoint inhibitors or beta-lactam antibiotics may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better monitoring and prevention of kidney injury in cancer patients, improving their overall treatment experience and outcomes.
How similar studies have performed: Previous research has indicated that understanding drug interactions and adverse effects in cancer treatments can lead to significant improvements in patient care, suggesting potential success for this approach.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Thelen, Haedi — University of Pennsylvania
- Study coordinator: Thelen, Haedi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.